

DIASORIN LAUNCHES FDA-CLEARED LIAISON CALPROTECTIN TEST IN THE US MARKET

January 31, 2019 - Saluggia (VC) - **DiaSorin** (FTSE MIB:DIA) is pleased to announce the US launch of the FDA-Cleared LIAISON Calprotectin test for the quantitative measurement of Calprotectin in stool samples.

Following the recently announced strategic collaboration with Meridian Bioscience to sell *Helicobacter pylori* stool antigen test, DiaSorin continues to expand its Gastro-Intestinal portfolio in the United States.

The LIAISON Calprotectin Assay can be used, in conjunction with information obtained from the patients' clinical evaluation and other diagnostic procedures, as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn's disease and ulcerative colitis, and as an aid in differentiation of IBD from irritable bowel syndrome (IBS).

IBD is a chronic condition with symptoms including chronic or recurrent episodes of abdominal pain and diarrhea. The incidence and prevalence of IBD are increasing in regions around the world, indicating its emergence as a global disease.

Since clinical manifestations of IBD are not specific and symptoms are often similar to other non-organic diseases such as IBS, traditionally costly and invasive endoscopic analysis has been used to confirm diagnosis. The non-invasive LIAISON Calprotectin test, thanks to its quantitative measurement of fecal calprotectin is an aid in the diagnosis of IBD allowing for more accurate use of more invasive and costly patient evaluations.

In 2018 Calprotectin test volumes in the US market were around 800,000, growing 30% year-on-year, although representing only 10% of the total US market potential for this test, when intended for the use of IBS and IBD differentiation.

The LIAISON Calprotectin is the second FDA-Cleared addition to the LIAISON Stool Diagnostic portfolio and it's available on the LIAISON XL, a fully automated platform, allowing for fast and high quality processing of patient samples. DiaSorin commits to the LIAISON Platform users, offering them the opportunity to streamline processes and consolidate specialty testing to one platform.

"The launch of the LIAISON Calprotectin test in the US represents a further step to enlarge our presence in the hospitals and expand our gastrointestinal stool panel offer on the American market" commented Carlo Rosa, Chief Executive Officer of DiaSorin Group. "The success gained with our gastro-intestinal offering drives us to continue the expansion of this panel worldwide as one of the main growth drivers for the future".

About DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years the Company has been developing, producing and marketing reagent kits for IVD worldwide.

The Group has a presence on the 5 continents with 24 companies, 5 foreign branches, 6 manufacturing facilities and 5 research centers throughout the world. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the "Diagnostic Specialist".

For additional information, please contact:

Riccardo Fava

Investor Relations & Corporate Communication Senior Director

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Ines Di Terlizzi

Investor Relator

Tel: +39.0161.487567

ines.diterlizzi@diasorin.it